Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
patient-donor derived probiotics
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
This investigational personalized probiotic therapy is being developed by the Institute of Hematology & Blood Diseases Hospital in China for the treatment of acute intestinal graft-versus-host disease (aGVHD). The therapy consists of *Lactobacillus* and *Bifidobacterium* probiotic strains derived from either the transplant patient or their donor. It is specifically designed to address intestinal dysbiosis in patients over 50 years of age who develop aGVHD following haploidentical hematopoietic stem cell transplantation (HSCT). By restoring a healthy gut microbiota composition, the therapy aims to modulate the intestinal microbiome and improve clinical outcomes and quality of life in this high-risk patient population.
- Other names
- patient-donor derived Lactobacillus and Bifidobacterium probioticspatient- and/or donor-derived probiotics
Beyond the preview
Go deeper on patient-donor derived probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on patient-donor derived probiotics.